Format

Send to

Choose Destination

See 1 citation found using an alternative search:

J Control Release. 2016 Oct 28;240:127-134. doi: 10.1016/j.jconrel.2015.11.018. Epub 2015 Nov 18.

Inhaled drug treatment for tuberculosis: Past progress and future prospects.

Author information

1
RTI International, Research Triangle Park, 3040 Cornwallis Road, NC 27709, United States. Electronic address: ahickey@rti.org.
2
RTI International, Research Triangle Park, 3040 Cornwallis Road, NC 27709, United States.
3
Brigham and Women's Hospital, Harvard University, 75 Francis Street, Boston, MA 02115, United States.

Abstract

Since the 1990s the rising incidence of multiple drug resistant TB, particularly in the context of human immunodeficiency virus co-infected patients, has threatened global TB control. At that time funding agencies began to support formal investigation of aerosol therapy which until then had been the subject of case reports of individual investigators. Over the last decade, proponents of aerosol therapy have increased in number within the TB research community as the incidence of multiple and extremely drug resistant TB has increased dramatically around the world. Aerosol therapy offers the potential to deliver drug at target concentrations directly into the lungs, use the alveolar-capillary interface to achieve systemic levels, while reducing the risk of systemic toxicity seen with parentally administered doses. In addition, there are insufficient new drugs in the pipeline to anticipate the appearance of a new regimen in time to assure future control of drug resistance. Consequently, alternative strategies are critical to achieving global TB control, and inhaled therapies should be considered as one such strategy.

KEYWORDS:

Aerosols; Antibiotics; Inhaled therapy; Mycobacterium tuberculosis; Pulmonary drug delivery; Tuberculosis

PMID:
26596254
DOI:
10.1016/j.jconrel.2015.11.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center